Heidelberg Pharma AG (ETR:HPHA)
4.380
+0.060 (1.39%)
Aug 22, 2025, 5:35 PM CET
Heidelberg Pharma AG Revenue
Heidelberg Pharma AG had revenue of 118.51K EUR in the quarter ending May 31, 2025, a decrease of -95.75%. This brings the company's revenue in the last twelve months to 4.18M, down -56.07% year-over-year. In the fiscal year ending November 30, 2024, Heidelberg Pharma AG had annual revenue of 6.85M, down -30.53%.
Revenue (ttm)
4.18M
Revenue Growth
-56.07%
P/S Ratio
48.80
Revenue / Employee
37.69K
Employees
105
Market Cap
204.13M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Nov 30, 2024 | 6.85M | -3.01M | -30.53% |
Nov 30, 2023 | 9.86M | -8.66M | -46.75% |
Nov 30, 2022 | 18.51M | 16.48M | 810.30% |
Nov 30, 2021 | 2.03M | -6.63M | -76.53% |
Nov 30, 2020 | 8.67M | 1.17M | 15.63% |
Nov 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Nov 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Nov 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Nov 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Nov 30, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Siemens Healthineers AG | 23.38B |
Merck KGaA | 21.22B |
Bayer Aktiengesellschaft | 46.17B |
Fresenius SE & Co. KGaA | 22.28B |
Fresenius Medical Care AG | 19.52B |
Sartorius Aktiengesellschaft | 3.47B |
Fielmann Group AG | 2.33B |
Carl Zeiss Meditec AG | 2.18B |
Heidelberg Pharma AG News
- 24 days ago - EQS-NVR: Heidelberg Pharma AG: Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution - Wallstreet:Online
- 4 weeks ago - EQS-DD: Heidelberg Pharma AG: Prof. Dr. Andreas Pahl, Acquisition of 90,000 shares through the exercise of 90,000 stock options under the 2011 stock option program (tranche 2; issue 2016) for ... - Wallstreet:Online
- 6 weeks ago - EQS-News: Heidelberg Pharma Reports on First Half-Year 2025 and the Positive Course of Business - Wallstreet:Online
- 3 months ago - EQS-News: Heidelberg Pharma Reports on the Results of the Ordinary Annual General Meeting 2025 and New Supervisory Board - Wallstreet:Online
- 3 months ago - EQS-News: Heidelberg Pharma to Present Promising New Clinical Data on its Lead ATAC Candidate HDP-101 at EHA 2025 - Wallstreet:Online
- 4 months ago - EQS-News: Heidelberg Pharma AG: Interim Statement on the First Three Months of Financial Year 2025 - Wallstreet:Online
- 5 months ago - EQS-News: Heidelberg Pharma to Present Data from its ADC Technology Platforms at AACR Annual Meeting 2025 - Wallstreet:Online
- 5 months ago - Heidelberg Pharma AG (XTER:HPHA) Full Year 2024 Earnings Call Highlights: Navigating Financial ... - GuruFocus